Mediastinal Node Metastasis Scoring in Non-Small Cell Lung Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current guidelines for mediastinal lymph node metastasis in lung cancer lack probability estimates based on combinations of risk factors such as tumor location, size, histological type, and age, leading to unnecessary invasive staging procedures.
Innovation Solution
A prediction model using clinical variables like patient age, tumor histology, tumor location, size, and lymph node stages from CT and PET-CT to calculate a mediastinal lymph node metastasis score, allowing non-invasive prediction of metastasis risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive mediastinal staging (EBUS-TBNA) is performed according to current guidelines, then the accuracy of lymph node metastasis diagnosis is improved, but the patient burden and procedural complexity increase
Solution Approach 1:
The prediction model performs preliminary assessment of lymph node metastasis risk using non-invasive clinical variables (age, tumor location, size, histology, CT/PET-CT findings) before invasive EBUS-TBNA procedures. This preliminary action identifies high-risk patients who truly need invasive staging, reducing unnecessary procedures and patient burden while maintaining diagnostic accuracy for those who require it
Solution Approach 2:
The prediction model acts as an intermediary between non-invasive clinical assessment and invasive EBUS-TBNA procedures. It processes multiple clinical variables and generates a probability score that mediates the decision-making process, determining which patients should proceed to invasive staging based on their predicted risk level
2Reliability
If invasive mediastinal staging is performed for all patients, then the reliability of treatment planning is improved, but the loss of time and increased procedural complexity worsen
Solution Approach 1:
The prediction model performs preliminary risk stratification using readily available clinical data before invasive procedures. This preliminary action identifies patients with high probability of metastasis who need invasive staging for reliable treatment planning, while avoiding unnecessary invasive procedures in low-risk patients, thereby reducing overall time loss without compromising treatment planning reliability for those who need it
Solution Approach 2:
The prediction model applies different assessment strategies to different patient subgroups based on their individual risk profiles. High-risk patients receive invasive staging for reliable treatment planning, while low-risk patients are managed with non-invasive assessment, optimizing the balance between treatment planning reliability and time efficiency for each patient locally rather than applying a uniform approach
3Measurement precision
If current guideline-based invasive staging is used, then the detection of metastasis is improved, but the device complexity and procedural invasiveness increase
Solution Approach 1:
The prediction model performs preliminary identification of high-risk patients using non-invasive clinical variables before invasive EBUS-TBNA procedures. This preliminary action ensures that invasive procedures are reserved for patients with high predicted probability of metastasis, maintaining detection precision while reducing the number of complex procedures required
Solution Approach 2:
The prediction model serves as an intermediary layer between simple clinical assessment and complex invasive EBUS-TBNA procedures. It processes multiple clinical variables and generates a probability score that determines which patients need invasive staging, thereby reducing the overall complexity of the staging pathway while maintaining metastasis detection capability for high-risk patients
Data Source
AI summary
The present disclosure relates to a method and apparatus for predicting mediastinal lymph node metastasis in non-small cell lung cancer based on information regarding a patient's age, a histological type of a tumor, a location of the tumor, a size of the tumor, a clinical lymph node stage determined by CT, and a clinical lymph node stage determined by PET-CT. According to an aspect of the present disclosure, a method and apparatus for predicting mediastinal lymph node metastasis in non-small cell lung cancer provides information on the presence of mediastinal lymph node metastasis in potentially operable lung cancer patients, specifically non-small cell lung cancer patients, and thus can be usefully used for decision-making on staging and treatment methods for non-small cell lung cancer patients, such as invasive mediastinal staging.